Sensational news heaved Surface Oncology (SURF) shares higher in the Postmarket hours

SFT Stock

Today, Surface Oncology (Nasdaq: SURF) surged 10.46% to 9.4 in the after-hours as it officially announced an agreement with GSK to develop and commercialize Surface Oncology’sOncology’s preclinical program, SRF813, an antibody that aims to inhibit PVRIG, an inhibitory protein expressed on natural killer cells (NK cells) and T cells. As part of the agreement, GSK […]